Azhar S, Reaven E
Department of Medicine, Stanford University School of Medicine, CA.
Biochem Pharmacol. 1988 Jun 15;37(12):2339-55. doi: 10.1016/0006-2952(88)90360-7.
This study was initiated to re-examine reported differences in the action of antimicrotubule agents on plasma protein secretion from livers of immature versus adult rats. The aim was (1) to determine the composition and to monitor the secretion of various plasma proteins and glycoproteins from liver slices labeled in vitro with specific amino acids and sugar residues, and (2) to correlate observed differences in secretion of these proteins with structural changes in the hepatocytes of the different aged animals. For the most part, slices of liver from fetal (term), neonatal (4- to 5 days old), and adult rats (70 days old) were incubated with radioactive amino acids or various tritiated sugars specific for N-linked core oligosaccharide and/or N-linked terminal oligosaccharide chains. Our findings indicate that liver slices of fetal and neonatal rats are efficient in synthesizing plasma proteins including fully glycosylated glycoproteins. The secretion of glycosylated and nonglycosylated proteins believed to be processed through Golgi complexes was inhibited to the same extent (approximately 70-80%) by antimicrotubule agents, regardless of the age of the host animal. However, other proteins and glycoproteins secreted by livers of immature rats were found to be relatively insensitive (i.e. inhibited to only 30-40%) to the action of various antimicrotubule drugs. The glycoproteins were found to lack N-linked terminal sugars (although the glycoproteins did contain N-linked core sugars), and it is likely that the drug-insensitive proteins bypassed critical glycosylating sites in the Golgi compartment prior to release. Overall, these findings support earlier data showing that antimicrotubule drugs have a special impact on Golgi-associated events in liver cells. To what extent these findings are related to the action of microtubules remains to be seen.
开展本研究是为了重新审视抗微管药物对未成熟大鼠与成年大鼠肝脏血浆蛋白分泌作用的报道差异。目的是:(1)确定用特定氨基酸和糖残基体外标记的肝切片中各种血浆蛋白和糖蛋白的组成,并监测其分泌情况;(2)将这些蛋白质分泌的观察差异与不同年龄动物肝细胞的结构变化相关联。在大多数情况下,将来自胎儿(足月)、新生(4至5日龄)和成年大鼠(70日龄)的肝切片与放射性氨基酸或各种用于N-连接核心寡糖和/或N-连接末端寡糖链的氚化糖一起孵育。我们的研究结果表明,胎儿和新生大鼠的肝切片能够有效地合成包括完全糖基化糖蛋白在内的血浆蛋白。无论宿主动物的年龄如何,抗微管药物对据信通过高尔基体复合体加工的糖基化和非糖基化蛋白的分泌抑制程度相同(约70-80%)。然而,发现未成熟大鼠肝脏分泌的其他蛋白质和糖蛋白对各种抗微管药物的作用相对不敏感(即仅被抑制30-40%)。发现这些糖蛋白缺乏N-连接末端糖(尽管这些糖蛋白确实含有N-连接核心糖),并且药物不敏感蛋白很可能在释放之前绕过了高尔基体区室中的关键糖基化位点。总体而言,这些发现支持了早期的数据,即抗微管药物对肝细胞中与高尔基体相关的事件有特殊影响。这些发现与微管作用的相关程度还有待观察。